Quoin Pharmaceuticals Ltd. (QNRX) stock
Close on Nov 13, 2026Market cap $7.43MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $7.43M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.26
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$19.59M
Trading
- Next earnings
- Mar 25, 2027 (estimated, during market hours)
- Previous close
- $3.75
- Open
- $3.68
- Day's range
- $3.55 – $3.99
- Volume
- 16,032
- Average volume (20 days)
- 11,614
- Beta (5 years)
- 1.01
- 52-week range
- $3.25 – $23.50
- RSI (14 days)
- 37.0
- Volatility (1 year)
- 109.3%
- Relative volume
- 0.04×
- WACC
- 10.2%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | QNRX | S&P 500 | Difference | QNRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -10.8% | -3.0% | −7.8 pts | ||
| 3 months | -38.8% | -2.8% | −36.1 pts | ||
| Year to date | -74.4% | +11.5% | −85.8 pts | ||
| 1 year | -72.4% | +13.5% | −85.9 pts | ||
| 3 years | -97.3% | +77.7% | −175.0 pts | -70.1% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -83.5% | +11.5% |
| 10 years | -100.0% | +308.2% | −408.2 pts | -68.6% | +15.1% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Quoin Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Update
About Quoin Pharmaceuticals
Pharmaceutical Preparations
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical business focused on developing and commercializing therapeutic solutions for rare and orphan diseases. The company concentrates on conditions that currently lack approved therapies or have very restricted treatment options. Its lead investigational asset, QRX003, is a topical lotion formulated to address rare genetic skin disorders, primarily Netherton Syndrome as well as Peeling Skin Syndrome. Quoin is also developing additional pipeline candidates, including QRX008 for scleroderma and QRX009, which utilizes topical rapamycin formulations for multiple rare conditions. Its target patient populations consist of individuals diagnosed with these rare medical disorders.
Company profile, executives and historyQuoin Pharmaceuticals stock: common questions
What is Quoin Pharmaceuticals's stock price?
QNRX closed at $3.70 on Nov 13, 2026, down 1.33% on the day. Over the past 52 weeks it traded between $3.25 and $23.50.
What is Quoin Pharmaceuticals's market cap?
Quoin Pharmaceuticals was worth $7.43M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
Does Quoin Pharmaceuticals pay a dividend?
No. Quoin Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Quoin Pharmaceuticals report earnings next?
Quoin Pharmaceuticals is expected to report Q4 FY2026 results on Mar 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has QNRX stock performed over the past year?
Including dividends, QNRX returned -72.4% over the past year, against +13.5% for the S&P 500.
Who are Quoin Pharmaceuticals's competitors?
Companies most similar to Quoin Pharmaceuticals by business, industry and size include PVLA, KPRX, MIRM, VRDN, SLGL.
See a number that looks wrong?